Literature DB >> 28340188

Commentary on "Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813".

Gianluca Marucci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28340188      PMCID： PMC5464435          DOI： 10.1093/neuonc/now313

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Authors:  Susan Chang; Peixin Zhang; J Gregory Cairncross; Mark R Gilbert; Jean-Paul Bahary; Carol A Dolinskas; Arnab Chakravarti; Kenneth D Aldape; Erica H Bell; David Schiff; Kurt Jaeckle; Paul D Brown; Geoffrey R Barger; Maria Werner-Wasik; Helen Shih; David Brachman; Marta Penas-Prado; H Ian Robins; Karl Belanger; Christopher Schultz; Grant Hunter; Minesh Mehta
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

2.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

3.  Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.

Authors:  David E Reuss; Annekathrin Kratz; Felix Sahm; David Capper; Daniel Schrimpf; Christian Koelsche; Volker Hovestadt; Melanie Bewerunge-Hudler; David T W Jones; Jens Schittenhelm; Michel Mittelbronn; Elisabeth Rushing; Matthias Simon; Manfred Westphal; Andreas Unterberg; Michael Platten; Werner Paulus; Guido Reifenberger; Joerg-Christian Tonn; Kenneth Aldape; Stefan M Pfister; Andrey Korshunov; Michael Weller; Christel Herold-Mende; Wolfgang Wick; Sebastian Brandner; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-06-19       Impact factor: 15.887

Review 4.  Isocitrate dehydrogenase mutations in gliomas.

Authors:  Matthew S Waitkus; Bill H Diplas; Hai Yan
Journal:  Neuro Oncol       Date:  2015-07-16       Impact factor: 13.029

5.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

6.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

Review 7.  What do we know about IDH1/2 mutations so far, and how do we use it?

Authors:  Craig Horbinski
Journal:  Acta Neuropathol       Date:  2013-03-20       Impact factor: 15.887

Review 8.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.